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Background. Lung transplant remains the only viable treatment for certain patients with
end-stage lung diseases. Such patients can become either single or double lung recipients.
The 2 procedures are associated with specific risks and benefits. The aim of the study was to
assess the survival of patients after lung transplant in a single center.
Methods. The retrospective study consists of 128 lung transplant recipients. Patients un-
derwent transplant between 2004 and 2017 because of following diseases: chronic obstructive
pulmonary disease (28.2%), cystic fibrosis (26.5%), and primary pulmonary hypertension
(12.3%), including idiopathic pulmonary arterial hypertension and interstitial lung diseases
(33%). Patients with idiopathic pulmonary arterial hypertension were not treated with
postoperative extracorporeal membrane oxygenation as left heart conditioning.
Results. Regardless of underlying disease, 75% of DLT recipients and 51% of SLT
recipients reached 5-year survival (P ¼ .0066). A total of 87% of lung transplant recipients
with cystic fibrosis reached 1-year survival. Among lung recipients with primary pulmonary
hypertension who underwent DLT and SLT, 5-year survival was reached by 84% and 51%,
respectively (P ¼ .025). Among patients with chronic obstructive pulmonary disease, 82%
of DLT recipients and 62% of SLT recipients reached 1-year survival (P ¼ .22). Patients
who received transplants because of primary pulmonary hypertension presented the
worst short-term survival among all SLT recipients.
Conclusions. Patients with CF have the best overall survival among all lung transplant
recipients. Double lung transplant provides statistically significantly better outcomes than
single lung transplant. This observation is also present among recipients who underwent
transplant because of primary pulmonary hypertension, as single lung transplant is not
recommended among such patients in particular.*Address correspondence to Magdalena Latos, MD, Medical
University of Silesia, Silesian Centre for Heart Diseases, ul. Marii
Skłodowskiej-Curie 9 Pawilon C, 41-800 Zabrze, Poland. Tel:
þ48667288893. E-mail: latos.magdalena93@gmail.comLUNG transplant is the only available treatment forcertain types of end-stage lung disease. Although
single lung transplants (SLTs) were the performed more
often during the time this therapeutic option first gained
recognition as a way of treatment, most present-day pro-
cedures are double lung transplants (DLTs) [1]. There are
some contraindications for performing SLT. Patients with
cystic fibrosis are eligible only to become double lung0
rg/10.1016/j.transproceed.2020.03.046recipients because of the characteristics of their disease.
On the other hand, patients with pulmonary fibrosis andª 2020 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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LUNG TRANSPLANT AND PULMONARY HYPERTENSION 2139chronic obstructive pulmonary disease (COPD) can
become a single lung recipient [2e4]. Available literature
reports various conclusions whether patients with those
diseases benefit more from either of these procedures
[4,5]. Some studies emphasize that in the scarcity of
organs for transplant, performing 2 SLTs can save 2
potential candidates [4]. Despite that, DLT is more
beneficial for more urgent candidates with high lung
allocation score [6]. Superior long-term survival is more
often observed after DLT [1,7]. Single lung procedures
are discouraged among patients with mean pulmonary
artery pressure exceeding 30 mm Hg [8]. DLT is also
reported to provide good outcomes for patients with pri-
mary pulmonary hypertension [9]. The aim of the studyTable 1. Demographic and Clinical Data of Patients W
Variables
Recipient age, median (IQR), y 3
Recipient BMI, median (IQR) 19.
Recipient pulmonary function at qualification
FEV1, median (IQR), % 2
FVC, median (IQR), % 4
6MWD, median (IQR), mile 302.
Donor age, mean (SD), y 40.5
Donor BMI, mean (SD) 23.6
Donor hemoglobin, mean (SD), g% 11.0
Donor serum creatinine, median (IQR), mg% 1.0
Duration of operation, median (IQR), h 12.8
Ventilation time, median (IQR), h 2
Total ischemia time, mean (SD), min 733.5
Recipient sex, No. (%)
Female 4
Male 4
Donor sex, No. (%)
Female 3
Male 5
Blood type matching, No. (%)
Compatible 1
Identical 6





Underlying disease, No. (%)
Chronic obstructive pulmonary disease 1
Cystic fibrosis 4
Interstitial lung disease 1
Idiopathic pulmonary arterial hypertension








Abbreviations: 6MWD, 6-minute walk distance; BMI, body mass index (calculate
expiratory volume in 1 second; FVC, forced vital capacity; IQR, interquartile range.was to assess the survival among double and single lung
recipients from a single center.METHODS
This retrospective study consisted of 128 lung transplant recipients
who received transplants between 2004 and 2017 in a single center.
Detailed characteristics pertaining to demographic and clinical
features of the studied group is presented in Table 1. Retransplants
and heart-lung transplants were excluded from the study. Patients,
who underwent SLT were statistically significantly older than those
after DLT. They also presented greater body mass index and forced
expiratory volume in 1 second at qualification. SLT as a surgical
procedure lasted shorter than DLT. Analysis assessed survival by
means of Kaplan-Meier estimators performed for the entireho Underwent Either SLT (n [ 38) or DLT (n [ 90)
DLT SLT P Value
5 (23.5) 50 (16.3) < .001
6 (4.86) 21.93 (6.53) < .001
4 (13.2) 30 (32.82) < .001
0 (25.2) 45 (26) .404
7 (153.12) 275.19 (141.96) .296
1 (11.93) 37.78 (13.62) .264
4 (2.91) 22.76 (2.6) .109
1 (2.47) 11.18 (2.6) .738
2 (0.75) 1.02 (0.73) .751
3 (2.5) 9.15 (2.84) < .001
4 (9.25) 17 (11.75) .004
1 (397.12) 536.91 (248.61) .009
.455
1 (45.56) 15 (39.47)
9 (54.44) 23 (60.53)
.369
6 (40) 12 (31.58)
4 (60) 26 (68.42)
.038
8 (21.43) 15 (39.47)
6 (78.57) 23 (60.53)
.208
0 (44.44) 16 (42.11)
8 (31.11) 18 (47.37)
5 (5.56) 1 (2.63)
7 (18.89) 3 (7.89)
.123
4 (15.56) 13 (34.19)
4 (48.89) 1(5.26)
0 (11.11) 8 (21.04)
8 (8.89) 8 (21.04)
1 (1.11) 0 (0)
1 (1.11) 0 (0)
4 (4.44) 3 (7.89)
2 (2.22) 1 (2.63)
2 (2.22) 0 (0)
2 (2.22) 2 (5.26)
1 (1.11) 2 (5.26)
1 (1.11) 0 (0)
d as weight in kilograms divided by height in meters squared); FEV1, forced
2140 ANTONCZYK, STĄCEL, URLIK ET ALpopulation as well as separately for DLT and SLT recipients who
underwent transplant because of COPD, interstitial lung disease
(ILD), and idiopathic pulmonary arterial hypertension (IPAH).
Patients with cystic fibrosis were included in a study of the general
population. However, there is no purpose in analyzing their survival
depending on type of procedure because there is only 1 single lung
recipient in the entire group. The classic threshold a ¼ .05 was
considered the level of significance.RESULTS
First analysis pertained to whether there is a difference
among survival depending on the type of the procedure
regardless of the underlying disease. Kaplan-Meier estima-
tion resulted in assessing that survival after DLT was sta-
tistically significantly better than that obtained after SLT
(P < .05). Detailed results are presented in Fig 1.
The same analysis was performed among patients who
became graft recipients because of COPD. Among this
group, results were not statistically significant (P ¼ .22) nor
were they among patients who received transplants because
of ILD (P ¼ .66). Survival analysis of those patients also
determined that there is no statistically significant difference
among recipients of either SLT or DLT (P ¼ .62).
Final analysis was performed among patients who became
either single lung recipients or double lung recipients
because of IPAH. There was a statistically significant dif-
ference in survival in favor of DLT recipients among this
group (P ¼ .0266). Detailed results are demonstrated in Fig
2. Additional statistical analysis was performed to evaluateFig 1. Kaplan-Meier estimation of survival among patients who und
double lung transplant; SLT, single lung transplant.the potential differences in characteristics of the patients
who underwent either DLT or SLT because of end-stage
IPAH. No statistically significant differences were found
among factors such as age of the recipient (Table 2). Pa-
tients who received transplants because of IPAH underwent
operation with cardiopulmonary support present only
intraoperatively. Extracorporeal membrane oxygenation
was not used as a postoperative left heart conditioning tool.DISCUSSION
Our study assessed that regardless of underlying disease,
DLT provides a greater survival benefit than single lung
procedure. This finding is consistent with the reports pre-
sented by the International Society of Heart and Lung
Transplantation [1]. They report that median survival after
DLT is 3 years longer than after SLT. What is more, the
difference between conditional survival is almost 4.5 years
in favor of DLT. Another statistically significant finding was
that there is no advantage in performing SLT among pa-
tients with pulmonary hypertension, which is supported by
studies published by Villavicencio et al and Nasir et al
[8,10]. Those studies discourage transplant facilities from
considering SLT among patients with pulmonary hyper-
tension. Our data consist of patients who received trans-
plants since 2004 up until 2017. During this time, none of
the patients underwent left heart conditioning with the
support of postoperative extracorporeal membrane
oxygenation. Our analysis should discourage othererwent either DLT or SLT regardless of underlying disease. DLT,
Fig 2. Kaplan-Meier estimation of survival among patients who underwent either DLT or SLT among patients with idiopathic form of
PAH. DLT, double lung transplant; PAH, pulmonary arterial hypertension; SLT, single lung transplant.
LUNG TRANSPLANT AND PULMONARY HYPERTENSION 2141transplant facilities from performing SLT for patients with
end-stage IPAH as well as other patients with severe pul-
monary hypertension. As also reported by the International
Society for Heart and Lung Transplantation Registry,Table 2. Demographic and Clinical Features at Qualification of Patient
Arterial Hype
Recipient Features at Qualification SLT
Age at qualification (MSD), y 33.63 
Age at transplant (MSD), y 34.63 
BMI (MSD), kg/m2 20.18 
Serum creatinine (Me  IQR), mg/dL 1.01 
INR (MeIQR) 1.85 
Hematocrit (MeIQR ), % 41.51 
Hemoglobin (MSD), g/dL 11.29 
NT-proBNP (MeIQR), pg/mL 2043.23 
6MWD (MSD), meters 394.50 
Oxygen saturation before 6MWT (MSD), % 94.00 
Oxygen saturation before 6MWT (MSD), % 86.25 
EF (LVEF) (MeIQR), % 59.17 
RVSP (MeIQR), mm Hg 90.50 
TAPSE (MeIQR), mm 16.83 
MPAP (MeIQR), mm Hg 57.29 
PCWP mean (MeIQR), mm Hg 13.00 
CI (MeIQR), L/min/m2 2.10 
CO (MeIQR), L/min 3.64 
Abbreviations: 6MWD, 6 minute walk test diatance; 6MWT e 6 minute walk test; BM
squared); CI, cardiac index; CO, cardiac output; DLT, double lung transplantation;
ejection fraction; M, mean; Me, median; MPAP, mean pulmonary artery pressure; NT
wedge pressure; RVSP, right ventricle pulmonary pressure; SD, standard deviation; SLpatients with IPAH present the worst short-term survival
after lung transplant among all underlying diseases [1]. Our
analysis did not prove that DLT is better therapeutic option
for patients with COPD than SLT. Similar findingss Undergoing Either SLT or DLT Because of Idiopathic Pulmonary
rtension
DLT P Value
12.28 37.40  8.53 .453
12.77 37.70  8.54 .549
2.60 22.56  3.32 .116
0.26 1.05  0.19 .759
0.51 1.79  1.08 .902
4.99 43.16  3.03 .397
3.00 13.21  3.28 .218
993.49 2144.68  1547.41 .895
75.41 354.00  115.03 .458
6.48 94.50  2.95 .841
6.90 84.70  10.60 .794
5.85 65.67  15.58 .351
23.77 80.17  18.81 .423
2.93 15.33  3.20 .375
18.87 61.09  12.69 .625
4.04 10.88  1.96 .208
0.52 2.53  0.55 .156
1.02 4.56  1.07 .113
I, body mass index (calculated as weight in kilograms divided by height in meters
INR, international normalized ratio; IQR- interquartile range; LVEF, left ventricle
-proBNP, N-terminal pro-B-type natriuretic peptide; PCWP, pulmonary capillary
T, single lung transplantation; TAPSE, tricuspid annular plane systolic excursion.
2142 ANTONCZYK, STĄCEL, URLIK ET ALpertaining to not only COPD but also pulmonary fibrosis
was presented by Aryal and Nathan [2]. Their work
concluded that lacking good-quality evidence makes it is
difficult to make strong recommendations. No statistically
significant difference was noted at 5-year survival among
DLT and SLT recipients who received transplants because
of COPD according to Schaffer et al [5]. On the other hand,
Crawford et al assessed that DLT is associated with sig-
nificant survival benefit in the assessment of 5-year mor-
tality [7]. Our study also did not acquire statistically
significant difference of survival among patients who
received transplants because of pulmonary fibrosis. Our
research showed no difference in survival among DLT and
SLT recipients because of ILD and particularly because of
idiopathic pulmonary fibrosis (IPF). There are studies
consistent with these findings. Chauhan et al presented the
study that concluded in stating there is no statistical dif-
ference in actuarial graft survival between recipients un-
dergoing DLT vs SLT because of IPF [4]. Such conclusion
is also present in an article published by Ranganath et al
[3]. On the other hand, studies by Schaffer et al and Vil-
lavicencio et al argue that DLT is the superior method of
lung transplant for every kind of pulmonary fibrosis and IPF
alone. The International Society of Heart and Lung
Transplantation presented the data of more than 18,000
lung transplant recipients with COPD. It was statistically
significant that DLT provides better survival [1]. Similar
results are reported regarding the diseases associated with
pulmonary fibrosis. Study of almost 3000 patients with ILD
but not idiopathic interstitial pneumonia and more than
14,000 patients with idiopathic interstitial pneumonia un-
deniably proves that DLT recipients have better survival [1].
CONCLUSIONS
Regardless of the underlying disease, DLT provides better
survival outcomes than SLT. The same observation was also
proved true for patients who underwent lung transplant
because of IPAH. It is advised not to perform SLT when
DLT is a viable option, especially for patients with severe
pulmonary hypertension.REFERENCES
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